Literature DB >> 27506704

The Utility of Cannabidiol in the Treatment of Refractory Epilepsy.

D S Reddy1.   

Abstract

Cannabis-derived cannabinoids such as cannabidiol (CBD) have anticonvulsant properties. Recently, there has been an emerging interest in the use of CBD-enriched products for treatment of drug-resistant epilepsy. Some pilot trials of CBD have proved beneficial for refractory epilepsy, but its efficacy is yet to be confirmed by standard placebo-controlled trials. However, the mechanisms underlying the seizure protection efficacy claims of CBD remain unclear. This review briefly describes the clinical utility of CBD in the treatment of refractory epilepsy.
© 2016 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27506704     DOI： 10.1002/cpt.441

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

Authors:  Leepakshi Khurana; Ken Mackie; Daniele Piomelli; Debra A Kendall
Journal:  Neuropharmacology       Date:  2017-05-17       Impact factor: 5.250

2.  Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP).

Authors:  Brian D Klein; Catherine A Jacobson; Cameron S Metcalf; Misty D Smith; Karen S Wilcox; Aidan J Hampson; John H Kehne
Journal:  Neurochem Res       Date:  2017-05-06       Impact factor: 3.996

3.  Cannabidiol reduces soman-induced lethality and seizure severity in female plasma carboxylesterase knockout mice treated with midazolam.

Authors:  Erica R Kundrick; Brenda M Marrero-Rosado; Marcio de Araujo Furtado; Michael Stone; Caroline R Schultz; Lucille A Lumley
Journal:  Neurotoxicology       Date:  2020-12-05       Impact factor: 4.294

4.  Cannabidiol's Upregulation of N-acyl Ethanolamines in the Central Nervous System Requires N-acyl Phosphatidyl Ethanolamine-Specific Phospholipase D.

Authors:  Emma Leishman; Meera Manchanda; Rachel Thelen; Sally Miller; Ken Mackie; Heather B Bradshaw
Journal:  Cannabis Cannabinoid Res       Date:  2018-11-30

5.  The C-terminal helix 9 motif in rat cannabinoid receptor type 1 regulates axonal trafficking and surface expression.

Authors:  Alexandra Fletcher-Jones; Keri L Hildick; Ashley J Evans; Yasuko Nakamura; Kevin A Wilkinson; Jeremy M Henley
Journal:  Elife       Date:  2019-04-30       Impact factor: 8.140

Review 6.  Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.

Authors:  María S García-Gutiérrez; Francisco Navarrete; Ani Gasparyan; Amaya Austrich-Olivares; Francisco Sala; Jorge Manzanares
Journal:  Biomolecules       Date:  2020-11-19

7.  Pharmacokinetics of Cannabidiol Following Intranasal, Intrarectal, and Oral Administration in Healthy Dogs.

Authors:  Dakir Polidoro; Robin Temmerman; Mathias Devreese; Marios Charalambous; Luc Van Ham; Ine Cornelis; Bart J G Broeckx; Paul J J Mandigers; Andrea Fischer; Jan Storch; Sofie F M Bhatti
Journal:  Front Vet Sci       Date:  2022-06-07

Review 8.  Review: Cannabinoids as Medicinals.

Authors:  Jag H Khalsa; Gregory Bunt; Kenneth Blum; Sanjay B Maggirwar; Marc Galanter; Marc N Potenza
Journal:  Curr Addict Rep       Date:  2022-09-07

Review 9.  Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?

Authors:  Emilio Perucca
Journal:  J Epilepsy Res       Date:  2017-12-31

10.  Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.

Authors:  Jerome Sarris; Justin Sinclair; Diana Karamacoska; Maggie Davidson; Joseph Firth
Journal:  BMC Psychiatry       Date:  2020-01-16       Impact factor: 3.630
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.